Baird analyst Jack Allen downgrades Cellectis (NASDAQ:CLLS) from Outperform to Neutral and lowers the price target from $39 to $10.
Baird Downgrades Cellectis to Neutral, Lowers Price Target to $10
Baird analyst Jack Allen downgrades Cellectis (NASDAQ:CLLS) from Outperform to Neutral and lowers the price target from $39 to $10.
Related Posts
Russian Ministry Website Hacked With The Message ‘Glory To Ukraine’
Amid the Russian invasion of Ukraine, the Russian Ministry of Construction, Housing and Utilities website was hacked with an internet search for the site leading to a sign-in page saying "Glory to Ukraine."
Alibaba, Pinduoduo Attract More Trouble From China
Bloomberg reports that Alibaba Group Holding Ltd (NYSE:BABA) and Pinduoduo Inc (NASDAQ:PDD) brace for more trouble as China seeks tighter intellectual…